Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Arcturus Therapeutics Holdings Inc.
< Previous
1
2
Next >
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
September 19, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
September 05, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
ASX:CSL
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
August 07, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023
July 24, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
June 01, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
May 09, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
April 26, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress
March 28, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023
March 07, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Attend Upcoming Investor Conferences
February 06, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
January 31, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 19, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
December 13, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
November 09, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Present at the Following Investor Conferences in November
November 07, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
November 01, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
October 26, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Attend the Following Investor Conferences
September 27, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Attend the Following Investor Conferences
September 01, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
August 31, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
August 18, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
August 09, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
August 01, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 21, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 20, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
May 09, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
May 05, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 22, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
April 20, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
March 25, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.